Tagrisso gets the green light for first-line lung cancer treatment in Europe

Last updated: 01 November 2019

You can legally access new medicines, even if they are not approved in your country.

Learn more »

Tagrisso (osimertinib) has been approved in Europe to treat Epidermal Growth Factor Receptor (EGFR) mutated non-small cell lung cancer (NSCLC) as a first-line treatment.

This offers a new line of attack at this stage of the disease (mutated lung cancer) and results from the trial show unprecedented survival benefit without progression of the disease in patients.

Find out more about the study, as well as the reach and impact of the medicine in this Pharmatimes Article.